Chemotherapy in EGFR-mutated NSCLC: optimizing combinations with TKIs and amivantamab

Nat Rev Clin Oncol. 2024 Mar;21(3):169-170. doi: 10.1038/s41571-023-00843-1.
No abstract available

MeSH terms

  • Antibodies, Bispecific* / therapeutic use
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Mutation
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • amivantamab-vmjw
  • Antibodies, Bispecific
  • ErbB Receptors
  • Protein Kinase Inhibitors
  • EGFR protein, human